The public health impact of Alzheimer's disease 2000-2050: Potential implication of treatment advances

被引:325
作者
Sloane, PD [1 ]
Zimmerman, S
Suchindran, C
Reed, P
Wang, L
Boustani, M
Sudha, S
机构
[1] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Sch Social Work, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA
[5] Univ N Carolina, Program Aging, Chapel Hill, NC 27599 USA
[6] Univ N Carolina, Greensboro, NC 27402 USA
关键词
public health impact; Alzheimer's disease; Alzheimer's care;
D O I
10.1146/annurev.publhealth.23.100901.140525
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Recent developments in basic research suggest that therapeutic breakthroughs may occur in Alzheimer's disease treatment over the coming decades. To model the potential magnitude and nature of the effect of these advances, historical data from congestive heart failure and Parkinson's disease were used. Projections indicate that therapies which delay disease onset will markedly reduce overall disease prevalence, whereas therapies to treat existing disease will alter the proportion of cases that are mild as opposed to moderate/severe. The public health impact of such changes would likely involve both the amount and type of health services needed. Particularly likely to arise are new forms of outpatient services, such as disease-specific clinics and centers. None of our models predicts less than a threefold rise in the total number of persons with Alzheimer's disease between 2000 and 2050. Therefore, Alzheimer's care is likely to remain a major public health problem during the coming decades.
引用
收藏
页码:213 / 231
页数:19
相关论文
共 51 条
  • [1] ALBERT SM, 2000, ASSESSING QUALITY LI
  • [2] Birks J, 2000, COCHRANE DB SYST REV
  • [3] BIRKS J, 2001, COCHRANE DATABASE SY
  • [4] Alpha-2 macroglobulin is genetically associated with Alzheimer disease
    Blacker, D
    Wilcox, MA
    Laird, NM
    Rodes, L
    Horvath, SM
    Go, RCP
    Perry, R
    Watson, B
    Bassett, SS
    McInnis, MG
    Albert, MS
    Hyman, BT
    Tanzi, RE
    [J]. NATURE GENETICS, 1998, 19 (04) : 357 - 360
  • [5] Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset
    Brookmeyer, R
    Gray, S
    Kawas, C
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 1998, 88 (09) : 1337 - 1342
  • [6] CLARK CM, 2000, NEURODEGENERATIVE DE
  • [7] Cleland JGF, 1999, AM J CARDIOL, V83, p112D
  • [8] A method for estimating progression rates in Alzheimer disease
    Doody, RS
    Massman, P
    Dunn, JK
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 449 - 454
  • [9] An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy
    During, MJ
    Symes, CW
    Lawlor, PA
    Lin, J
    Dunning, J
    Fitzsimons, HL
    Poulsen, D
    Leone, P
    Xu, RA
    Dicker, BL
    Lipski, J
    Young, D
    [J]. SCIENCE, 2000, 287 (5457) : 1453 - 1460
  • [10] Ernst RL, 1997, ALZ DIS ASSOC DIS, V11, P135